These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34597525)

  • 21. Neutralizing Antibody Therapeutics for COVID-19.
    Hurt AC; Wheatley AK
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33916927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce.
    White H; McDonald SJ; Barber B; Davis J; Burr L; Nair P; Mukherjee S; Tendal B; Elliott J; McGloughlin S; Turner T
    Med J Aust; 2022 Oct; 217(7):368-378. PubMed ID: 36150213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients.
    Bahakel H; Murphy C; Frenck RW; Grimley MS; Marsh RA; Paulsen GC; Haslam DB; Phillips CL; Courter J; Spearman P; Schulert G; Danziger-Isakov L
    Pediatr Infect Dis J; 2022 Dec; 41(12):985-988. PubMed ID: 36219876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
    J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies.
    Chatterjee S; Choudhury S; Das D
    Indian J Pharmacol; 2022; 54(1):51-57. PubMed ID: 35343208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remdesivir for the treatment of COVID-19.
    Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
    Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
    Juul S; Nielsen EE; Feinberg J; Siddiqui F; Jørgensen CK; Barot E; Holgersson J; Nielsen N; Bentzer P; Veroniki AA; Thabane L; Bu F; Klingenberg S; Gluud C; Jakobsen JC
    PLoS One; 2021; 16(3):e0248132. PubMed ID: 33705495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients.
    Bellino S
    Ann Med; 2022 Dec; 54(1):2856-2860. PubMed ID: 36259490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis.
    Scholl AR; Korentzelos D; Forns TE; Brenneman EK; Kelm M; Datto M; Wheeler SE; Carlsen ED
    J Appl Lab Med; 2022 Oct; 7(6):1379-1387. PubMed ID: 35993812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
    O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
    Wolf J; Abzug MJ; Wattier RL; Sue PK; Vora SB; Zachariah P; Dulek DE; Waghmare A; Olivero R; Downes KJ; James SH; Pinninti SG; Yarbrough A; Aldrich ML; MacBrayne CE; Soma VL; Grapentine SP; Oliveira CR; Hayes M; Kimberlin DW; Jones SB; Bio LL; Morton TH; Hankins JS; Maron GM; Timberlake K; Young JL; Orscheln RC; Schwenk HT; Goldman DL; Groves HE; Huskins WC; Rajapakse NS; Lamb GS; Tribble AC; Lloyd EC; Hersh AL; Thorell EA; Ratner AJ; Chiotos K; Nakamura MM
    J Pediatric Infect Dis Soc; 2021 May; 10(5):629-634. PubMed ID: 33388760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.
    Rosas IO; Diaz G; Gottlieb RL; Lobo SM; Robinson P; Hunter BD; Cavalcante AW; Overcash JS; Hanania NA; Skarbnik A; Garcia-Diaz J; Gordeev I; Carratalà J; Gordon O; Graham E; Lewin-Koh N; Tsai L; Tuckwell K; Cao H; Brainard D; Olsson JK
    Intensive Care Med; 2021 Nov; 47(11):1258-1270. PubMed ID: 34609549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.